Log inSign up
AAOIFI No. 21 screening

Is SLS halal?

SELLAS Life Sciences Group, Inc

Doubtful

No clear verdict is possible for SELLAS Life Sciences Group, Inc — data is insufficient or the case is contested in fiqh. As a precaution it is NOT included in the halal list.

Checked: 15 October 2026

Exchange

NASDAQ

Price

9.98

Day

-11.99%

Market cap

$2.30B

Industry

Biotechnology

Sector

Healthcare

What the company does

SELLAS Life Sciences develops cancer immunotherapies (galinpepimut-S, an acute myeloid leukemia vaccine) and SLS009, in clinical trials. No revenue; funded by investors.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $468.82M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $138.34M ÷ 36-month average market cap $468.82M = 29.5%

    29.5%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $2.30B.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historySLS's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →